Drug Trial Radar · NCT06788522
The Effects of Orexin Antagonism on Fear Extinction in PTSD
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40,120
Planned (sponsor's estimate)
Start
Jul 1, 2026
Primary completion
Mar 1, 2032
Study completion Jun 30, 2032
Sponsor
- Lead sponsor
- VA Office of Research and DevelopmentFederal agency
- Sponsor type
- Federal agency
- First posted
- Jan 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
PTSD affects approximately 22% of Veterans who have served in Iraq and Afghanistan. Symptoms of PTSD may include re-experiencing, avoidance of trauma reminders, negative thoughts or feelings, and hyperarousal, such as increased startle reactivity and disturbed sleep. Treatments for PTSD are based on fear extinction principles in which individuals are repeatedly exposed a feared cue in the absence of danger, resulting in diminishing physiological reactions, a process believed to underlie recovery from PTSD. Studies suggest that orexin, a wake-promoting neuropeptide, may enhance fear extinction. This study will examine whether suvorexant, a selective orexin-receptor antagonist, will enhance fear extinction in Veterans with PTSD and insomnia. Finding a role for orexins in fear extinction will support the rationale for its further evaluation in the treatment of PTSD. Suvorexant is an accessible, safe medication that has been well-established in treating insomnia. It has outstanding promise for treating common and distressing symptoms in Veterans with PTSD.
Conditions
- Insomnia
- PTSD
Interventions
SuvorexantDrug
Suvorexant pills (10-20 milligrams)
PlaceboDrug
Matching placebo pills
Primary outcomes
What the sponsor says the trial is designed to measure.
- EnrollmentTime frame: Month 4-23
- Medication AdherenceTime frame: Month 4-23
- Side effect reportsTime frame: Month 4-23
- Post-randomization drop outTime frame: Month 4-23
- Fear conditioning and extinctionTime frame: Month 4-23
- Rates of technical malfunctionTime frame: Month 4-23
- Electrodermal ActivityTime frame: Years 2-7
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
San Francisco VA Medical Center, San Francisco, CA
San Francisco, California · Recruiting
Ralph H. Johnson VA Medical Center, Charleston, SC
Charleston, South Carolina · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.